ESPR Esperion Therapeutics, Inc.: Bathi saben saham sajroning taun lumaku

Esperion Therapeutics (ESPR) develops cholesterol-lowering drugs through licensing alliances and patent acquisitions. The 12-month EPS growth trend on the GURU.Markets platform chart clearly visualizes the trajectory, where 93.10 reflects the latest metric value. Working capital stabilization has halted the depletion of reserves, while a classic scalability model will ensure profitability following the mass market launch of the medications.
Rincian metrik keuangan lan pasar Esperion Therapeutics (ESPR)

This indicator reflects the change in net earnings per share over the last twelve months, allowing for an assessment of capital generation efficiency and the determination of the business's fair value considering long-term operational risks. The investor analyzes the annual growth rate of EPS (TTM) for Esperion Therapeutics (ESPR) to forecast the control premium, linking yield growth to the market success of the Nexletol and Nexlizet drugs.